Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1472-6963
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries ; volume:22 ; number:1 ; day:4 ; month:11 ; year:2022 ; pages:1-9 ; date:12.2022
BMC health services research ; 22, Heft 1 (4.11.2022), 1-9, 12.2022

Creator
Yoo, Hyun Kyeong
Byun, Han Geul
Caprioli, Flavio
Fumery, Mathurin
Peyrin-Biroulet, Laurent
Sreedhar, Subramanian
Potter, James
Jang, Minyoung
Contributor
SpringerLink (Online service)

DOI
10.1186/s12913-022-08683-y
URN
urn:nbn:de:101:1-2023011921551020075445
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Yoo, Hyun Kyeong
  • Byun, Han Geul
  • Caprioli, Flavio
  • Fumery, Mathurin
  • Peyrin-Biroulet, Laurent
  • Sreedhar, Subramanian
  • Potter, James
  • Jang, Minyoung
  • SpringerLink (Online service)

Other Objects (12)

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration

Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration

Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era

Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era

Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial

Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial

Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients

Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients

Tonina, Structure E5-5 (TNA: Str. E5-5)

Bauwerk

Tonina, Structure E5-5 (TNA: Str. E5-5)

Recherchebericht zum Futterladewagen E5 (FLW - E5).- Bericht von Wichmann

Schriftgut

Recherchebericht zum Futterladewagen E5 (FLW - E5).- Bericht von Wichmann

Kassenbuch, Einnahmen E5

Archivale

Kassenbuch, Einnahmen E5

NL 45/E5

Kapitel

NL 45/E5

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching

Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease

Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease

Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

Related objects